Genmab Website
Find more information about all of Genmab's products on our website at genmab.com.
Genmab Medical Information
Submit a question to Genmab Global Medical Information
Pipeline
DuoBody Technology Platform
®
DuoBody -PD-L1x4-1BB (GEN1046)
®
MOA Videos
Tisotumab Vedotin
Subcutaneous (SC) Epcoritamab Induces Complete Responses Across R/R B-Cell NHL Subtypes: Updated Dose-Escalation Data
Presentation details:
Sunday, February 21, 2021
Time: 15:30–17:00 JST
Martin Hutchings, MD, PhD
Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
Phase I/IIa Trial Evaluating Safety and Clinical Activity of
DuoBody -PD-L1×4-1BB (GEN1046) in Advanced Solid Tumors
®
Presentation details:
Sunday, February 21, 2021
Time: 08:30–09:25 JST
Ignacio Melero, MD
Department of Immunology, Clinica Universidad de Navarra Pamplona, Spain
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer: Phase 2 innovaTV 204 Study Results
Ignace Vergote, MD, PhD
Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute
Leuven, Belgium
Presentation details:
Saturday, February 20, 2021
Time: 15:30–17:35 JST
Japanese Society of Medical Oncology (JSMO)
Virtual Annual Meeting
February 18–21, 2021
Online materials available until March 31, 2021
© 2021 Genmab A/S